The ESMO data5 Sep 2021 12:47
Just looking at the ESMO late breaking abstract pages again , and they way it reads , the data that Faron have submitted should be pretty good I think .
Firstly , we have submitted a LBA to start with , so obviously some good data .
Not every abstract gets to present .
From the site :
The ESMO 2021 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:
Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
e-Poster – e-Posters will be on display on the Congress platform for consultation as of 16 September.
So the importance goes from cutting edge , to superior , to good , to just being posted .
We have been chosen in the Proffered Paper category - original data of superior quality ( better than good ), and are one of only 3 chosen for that category .
The other interesting thing about LBA's is this :
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 14 May 2021 will be considered for late-breaking status.
So , to be accepted for LBA - and to get selected for a Proffered Paper selection , the data needs to be new , of superior quality , and something that was not known on 14 May 2021 .
Considering we knew about Bex's ability to reduce Clever 1 , and to reduce solid tumours in May , I'm thinking this new data has to be related to soluble clever 1 , and findings relating to upping the dosing and frequency to 1 week in order to maintain suppression of clever 1 .
If it is , that would be superior indeed - and a real big step for us ££££ .
If it isn't , then it has to be something else , which we don't even know that they are researching yet . More unlikely , but again can only be good .
But Faron have known about Soluble Clever 1 for nearly 8 months , and back on 20th Jan , notified that they planned to up the frequency of dosing to combat it .
The new discovery of the role of soluble Clever-1 as an immune suppressive molecule is striking, indicating the soluble part of this receptor could cause systemic inhibition of T-cells in all locations of body, therefore controlling the general immune capacity in cancer patients. We hope to be able to overcome this inhibition just by increasing the dosing frequency of bexmarilimab to provide maximal binding and the removal of Clever-1 from body fluids and tissues, including tumours
Its the big piece of data that we have all been waiting for - and is overdue .
If I was a betting man.......
Sign In
Follow the stocks
